Literature DB >> 23756631

Acceptability of psychotherapy, pharmacotherapy, and self-directed therapies in Australians living with chronic hepatitis C.

Benjamin J R Stewart1, Deborah Turnbull, Antonina A Mikocka-Walus, Hugh A J Harley, Jane M Andrews.   

Abstract

Despite the prevalence of psychiatric co-morbidity in chronic hepatitis C (CHC), treatment is under-researched. Patient preferences are likely to affect treatment uptake, adherence, and success. Thus, the acceptability of psychological supports was explored. A postal survey of Australian CHC outpatients of the Royal Adelaide Hospital and online survey of Australians living with CHC was conducted, assessing demographic and disease-related variables, psychosocial characteristics, past experience with psychological support, and psychological support acceptability. The final sample of 156 patients (58 % male) had significantly worse depression, anxiety, stress, and social support than norms. The most acceptable support type was individual psychotherapy (83 %), followed by bibliotherapy (61 %), pharmacotherapy (56 %), online therapy (45 %), and group psychotherapy (37 %). The most prominent predictor of support acceptability was satisfaction with past use. While individual psychotherapy acceptability was encouragingly high, potentially less costly modalities including group psychotherapy or online therapy may be hampered by low acceptability, the reasons for which need to be further explored.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756631     DOI: 10.1007/s10880-012-9339-7

Source DB:  PubMed          Journal:  J Clin Psychol Med Settings        ISSN: 1068-9583


  49 in total

1.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.

Authors:  D M Evon; K M Simpson; D Esserman; A Verma; S Smith; M W Fried
Journal:  Aliment Pharmacol Ther       Date:  2010-09-17       Impact factor: 8.171

2.  The impact of client treatment preferences on outcome: a meta-analysis.

Authors:  Joshua K Swift; Jennifer L Callahan
Journal:  J Clin Psychol       Date:  2009-04

3.  Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.

Authors:  L Castera; A Constant; C Henry; P Champbenoit; P-H Bernard; V De Ledinghen; J Demotes-Mainard; P Couzigou
Journal:  Aliment Pharmacol Ther       Date:  2006-10-15       Impact factor: 8.171

Review 4.  Natural history of hepatitis C.

Authors:  David L Thomas; Leonard B Seeff
Journal:  Clin Liver Dis       Date:  2005-08       Impact factor: 6.126

5.  Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.

Authors:  S Chainuvati; S K Khalid; S Kancir; M Shea; J Edwards; M Sernyak; S Wongcharatrawee; G Garcia-Tsao
Journal:  J Viral Hepat       Date:  2006-04       Impact factor: 3.728

6.  Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.

Authors:  C L Raison; B J Woolwine; M F Demetrashvili; A S Borisov; R Weinreib; J P Staab; J M Zajecka; C J Bruno; M A Henderson; J F Reinus; D L Evans; G M Asnis; A H Miller
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

7.  Depression, fatigue, and functional disability in patients with chronic hepatitis C.

Authors:  M M Dwight; K V Kowdley; J E Russo; P S Ciechanowski; A M Larson; W J Katon
Journal:  J Psychosom Res       Date:  2000-11       Impact factor: 3.006

8.  The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.

Authors:  Heather F Gidding; Libby Topp; Melanie Middleton; Kate Robinson; Margaret Hellard; Geoffrey McCaughan; Lisa Maher; John M Kaldor; Gregory J Dore; Matthew G Law
Journal:  J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 4.029

9.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

Authors:  P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

10.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

View more
  1 in total

1.  An Aggravated Trajectory of Depression and Anxiety Co-morbid with Hepatitis C: A Within-groups Study of 61 Australian Outpatients.

Authors:  Benjamin J R Stewart; Deborah Turnbull; Antonina A Mikocka-Walus; Hugh Harley; Jane M Andrews
Journal:  Clin Pract Epidemiol Ment Health       Date:  2015-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.